Physician profile
Alan Marquez
NPI 1972170595
$1,088.67
in general payments reported to CMS, 2019-2025
13 companies · $882 in 2025
The $882 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $17.93 · 2024: $189 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,089.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,088.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $302.52 | 2024-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $173.37 | 2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $124.60 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $109.32 | 2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.59 | 2025 | Jardiance |
| Exact Sciences Corporation | $71.67 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $70.48 | 2023-2025 | |
| Amgen INC. | $43.99 | 2025 | Evenity, Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $36.33 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.62 | 2025 | |
| Averitas Pharma INC. | $23.51 | 2025 | Qutenza |
| Kowa Pharmaceuticals America, INC. | $16.00 | 2025 | Zoryve |
| Aimmune Therapeutics, INC. | $14.67 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Marquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.